Overview of C Retard

What is C Retard? — Overview and Identity

Property	Description
Active ingredient	Ascorbic acid (as Sodium Ascorbate)
Form	Retard tablet (Modified-release preparation)
Pharmacological class	Vitamin; Water-soluble vitamin
General purpose	Nutritional support; Correction of deficiency
Origin	Synthetic (Essential nutrient)

C Retard: Classification and Core Composition

C Retard is defined as a pharmaceutical preparation belonging to the high-level pharmacological group of water-soluble vitamins, primarily utilized for nutritional support. The active compound is the essential nutrient Ascorbic acid (INN), commonly known as Vitamin C, which is present in this formulation as the salt, Sodium Ascorbate. As an essential nutrient, this substance is central to addressing nutritional requirements.

The active substance is critically important due to its potent antioxidant activity and its function as a cofactor in enzymatic reactions, particularly those necessary for collagen synthesis. The Sodium Ascorbate form is a buffered alternative to free Ascorbic acid, which is used for potentially minimizing gastric discomfort when taken in higher doses. This focus on patient tolerability differentiates the formulation.

What is a Retard Tablet and Why is it Used?

C Retard is specifically an oral retard tablet, classifying it as a modified-release preparation dosage form. This design feature means the tablet is engineered to deliver the active compound, Sodium Ascorbate, slowly and consistently over many hours within the body. This sustained-release technology is intended to achieve more consistent blood concentrations than immediate-release forms.

This prolonged-release preparation is functionally distinct from standard immediate-release forms, ensuring a more stable and continuous absorption of the essential nutrient. Sustained-release formulations can optimize the systemic delivery of active ingredients, improving the efficiency of the supplementation. This targeted delivery approach makes it suitable for individuals requiring reliable, all-day immune function support or continuous assistance in preventing hypovitaminosis C.

Regulatory References

The Science Behind Sustained-Release Medications

What side effects are possible with C Retard?

Possible Side Effects and Safety Information

The safety profile for Ascorbic acid (Vitamin C), the active ingredient in C Retard, is based on classifications from authoritative government regulatory documents.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by their documented frequency. Common or less common effects often involve the gastrointestinal system, including nausea, diarrhea, abdominal pain, and sometimes headache. Rarer reactions, such as skin rash or urticaria (hives), fall into the less common or rare categories.

System-Organ Class and Safety Considerations

The documented adverse reactions are grouped into System-Organ Classes, with key involvement of the Gastrointestinal Disorders and Renal and Urinary Disorders systems. Safety documents highlight specific risks for certain patient groups and conditions:

Serious Adverse Reactions: Regulators document the potential for oxalate nephrolithiasis (kidney stone formation), which is primarily associated with prolonged, high-dose use. A specific, rare, but serious risk is acute hemolytic anemia in patients with a genetic condition known as Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Population-Specific Constraints: The safety profile requires caution for individuals with pre-existing renal impairment or a history of oxalate stone formation due to the increased risk of nephrolithiasis. Furthermore, caution is warranted in patients with hereditary hemochromatosis.

Safety Profile Summary

This medicine's official safety structure emphasizes that while mild, non-serious gastrointestinal complaints are the most frequently documented side effects, the more critical safety considerations are linked to the renal system and specific hematological conditions. These restrictions formally limit or caution use in sensitive patient populations, as defined in regulatory labeling.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes that an overdose with zolpidem, the active ingredient in C Retard, can result in effects ranging from mild central nervous system (CNS) depression to severe, life-threatening conditions.

Documented Overdose Presentations and Risks

The primary presentation of overdose involves an impairment of consciousness that can range from somnolence (drowsiness) to a light or profound coma. Regulatory sources note that a single-drug overdose with zolpidem generally results in recovery, but severe outcomes have been reported, especially when the drug is taken with other CNS depressant agents, including alcohol.

Overdose has been associated with the risk of cardiovascular and/or respiratory compromise. The most serious risks are the potential for a fatal outcome due to respiratory depression and cardiorespiratory collapse.

When to Seek Immediate Medical Help

Any suspected overdose with C Retard must be treated as a medical emergency. Immediate medical attention is required due to the reported risks of serious outcomes, including respiratory difficulty, cardiovascular compromise, and fatal consequences. Emergency actions, as outlined in official labeling, include providing general symptomatic and supportive measures, and in certain cases, immediate procedural steps like gastric lavage or the cautious use of an antidote such as flumazenil.

The information above is based strictly on overdose statements found in authoritative governmental regulatory documents.

Therapeutic Uses of C Retard

Quick Facts

Addresses Deficiencies: Helps manage and prevent conditions linked to insufficient intake of Vitamin C (ascorbic acid).
Supports Wellness: Contributes to the maintenance of general body function and overall health.
Dietary Adjuvant: Suitable for use when dietary intake of Vitamin C is considered inadequate.

What C Retard Treats: Main Uses and Benefits

C Retard is a therapeutic agent containing Vitamin C (ascorbic acid) intended to support the management of various conditions related to a nutritional gap. Its primary role is in the prevention and treatment of Vitamin C deficiency. When diet does not provide sufficient amounts of this essential nutrient, this product is utilized to restore appropriate levels.

The maintenance of adequate Vitamin C status is necessary for the performance of several normal biological functions within the body. It plays a role in the formation of collagen, a protein vital for connective tissue, as well as supporting the absorption of iron from the digestive system. Additionally, maintaining sufficient Vitamin C may contribute to the normal function of the body’s natural defenses and supports the repair process of tissues, which is a required step for wound recovery.

This medication is appropriate for use as an adjuvant treatment when increased requirements for Vitamin C are clinically identified or when an individual's diet is determined to be limited in this nutrient. The formulation is designed for an extended-release profile, which is thought to assist the body's ongoing assimilation of the ingredient.

Eligibility and Restrictions for Use

Who can and cannot use C Retard? — Official Regulatory Information

This section outlines the eligibility criteria and contraindications for C Retard based on official government regulatory documents.

Populations Who Must Not Use This Medicine (Contraindications)

Use of this medicine is strictly prohibited (contraindicated) for individuals with the following conditions:

Hypersensitivity: Known allergy to the active substance (ascorbic acid) or any of the non-active ingredients (excipients) in the formulation.
Oxalate Urolithiasis: Suffering from or having a history of oxalate-containing bladder or kidney stones.
Iron Storage Disorders: Conditions involving pathological iron storage in the body, such as hemochromatosis, thalassemia, or sideroblastic anemia.

Restricted or Non-Recommended Use

Eligibility is limited or use is not recommended for certain groups due to potential risks if standard doses are exceeded:

Children: The dosage is considered unsuitable for children and adolescents under 13 years of age.
Renal Impairment: Patients with severe kidney failure or those on dialysis must not exceed very low daily doses (typically 50–100 mg) due to the risk of oxalate crystal formation.
G6PD Deficiency: Use is restricted in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency; high doses must be avoided to prevent hemolysis.

Pregnancy and Lactation

Use during pregnancy and breastfeeding is generally permitted only to correct a diagnosed vitamin C deficiency, and the recommended daily dosage must not be exceeded.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for C Retard (Ascorbic Acid) is defined by documented effects on the systemic exposure and pharmacodynamics of certain co-administered substances, as formalized in government regulatory documents.

Interaction Scope and Restrictions

Category	Documented Interaction Entities
Exposure-Altering Substances	Iron preparations and supplements; Aluminum-containing Antacids; Estrogens (Ethinyl estradiol); Amphetamine.
Pharmacodynamic Risk	Deferoxamine (Desferrioxamine).
Procedural Constraint	Diagnostic Tests (Lab interference).

Official Interaction Statements: Co-administration with Iron preparations results in increased oral iron absorption. This alteration of metal exposure also applies to Aluminum-containing Antacids, where the systemic absorption of aluminum is increased, a combination specifically not recommended in patients with renal impairment due to the risk of accumulation.

The concomitant use of high-dose Ascorbic acid with Deferoxamine is associated with an increased risk of severe cardiovascular adverse effects, requiring clinical monitoring in patients with chronic iron overload.

Furthermore, C Retard can modify the concentration of other medicines: it may increase the serum level of Ethinyl estradiol and may decrease the level of certain drugs sensitive to urinary pH changes, such as Amphetamine. A key procedural constraint is the required cessation of C Retard administration prior to specific diagnostic laboratory tests (e.g., urine glucose) to prevent false results due to interference.

Mechanism of Action

C Retard is a sustained-release formulation of Ascorbic Acid (Vitamin C); its mechanism of action involves interaction with specific enzyme systems and cellular defense pathways.

Redox Modulation and Direct Antioxidant Protection

This core mechanism involves the drug acting as a reductant, directly neutralizing free radicals and reactive oxygen species (ROS) via electron donation, leading to the reduction of oxidative species. This action assists in maintaining the reduced state of macromolecules and influences redox activity within the immune and endothelial systems.

Cofactor for Collagen and Tissue Synthesis

Ascorbic acid is required as a cofactor for hydroxylase enzymes (such as prolyl and lysyl hydroxylase), which are necessary for the post-translational modification of procollagen. This process facilitates the cross-linking of mature collagen, which establishes the necessary structure for connective tissues and influences cascades involved in tissue repair.

Modulation of Neurotransmitter Biosynthesis

Ascorbic acid participates as a reductant cofactor for key enzymes, including Dopamine beta-hydroxylase. By supporting this enzyme, the mechanism is involved in the conversion of dopamine to norepinephrine (noradrenaline). This mechanism participates in modulating activity within specific central and peripheral pathways, influencing neural and hormonal signaling responses.

Dosage and Administration Information

C Retard is exclusively intended for oral administration. As a modified-release (retard) preparation, the use protocol is engineered to deliver the active ingredient, Ascorbic acid, over a prolonged period, which results in a once daily frequency.

The integrity of this formulation is critical to proper usage; therefore, the tablet must be swallowed whole and must not be crushed, split, or chewed under any circumstances. The dose should be ingested with a full glass of water, and while it may be taken with or without food, taking it alongside a meal is acceptable.

The standard administration dose for high-level supplementation often utilizes the 500 mg unit. A limit exists stating that the total daily intake of ascorbic acid from all sources should not exceed 2,000 mg (2 g). For those addressing an established deficiency, the treatment course typically requires a minimum of two weeks of continuous daily dosing.

Population-specific constraints govern usage in patients with compromised kidney function. For individuals with severe renal impairment or those undergoing dialysis, the dose is strictly limited to a low daily amount (e.g., 50 mg to 100 mg). Should a dose be missed, the procedure is to take it when remembered, but to skip it entirely if the next dose is due, ensuring that a double dose is never taken.

Recent Clinical Evidence

Research Evidence / Overview of Studies for C Retard

This section outlines the types of research conducted on ascorbic acid (the active ingredient in C Retard) and summarizes what official and peer-reviewed sources report, strictly avoiding clinical advice or recommendations.

Evidence for Preventing and Treating Vitamin C Deficiency

The foundational role of ascorbic acid in the body is addressed in research that was studied for the prevention and treatment of a full deficiency (scurvy) and sub-optimal vitamin status.

The earliest understanding of this essential nutrient is derived from historical human depletion and repletion studies, which involved observing volunteers on diets severely restricted in Vitamin C. Researchers also relied on case reports and observational settings to understand patterns following the introduction of the vitamin to deficient individuals. Modern systematic reviews and meta-analyses summarize the findings from multiple supplementation trials conducted in populations with low or sub-optimal Vitamin C levels.

Research on Symptom Resolution and Biomarker Changes

In these studies, researchers examined two main types of outcomes: clinical signs and biomarkers. Clinical observations were used in research exploring how symptoms change over time, such as noting the resolution of physical signs like fatigue or changes in gum health and wound repair. Simultaneously, studies monitored biomarkers by measuring the concentration of ascorbic acid in the blood plasma and in specific immune cells (leukocytes).

Research was observed in some studies to result in the re-establishment of normal biomarker levels following the re-introduction of the nutrient. The evidence for treating severe deficiency is drawn from long-standing research and The research base for this indication is classified as established in major regulatory guidelines. However, data for certain groups remain insufficient and there is a limited number of large-scale contemporary Randomized Controlled Trials (RCTs) specifically focused on the treatment of the most severe deficiency state (scurvy).

Studies on the Modified-Release (Retard) Tablet Design

C Retard is a modified-release tablet, and specific research was evaluated in small-scale studies to characterize how this specialized design delivers ascorbic acid. This research focused on the drug delivery profile rather than long-term clinical outcomes related to systemic or functional imbalance.

These trials typically used a comparative design where the retard tablet was observed in relation to a standard, immediate-release formulation. Researchers examined how the rate and total amount of ascorbic acid absorbed varied between the two forms. Outcomes describing episodic or acute changes in the concentration of ascorbic acid in the bloodstream were measured, including the maximum level reached (Cmax) and the time it took to reach that level (Tmax).

Data show patterns related to the retard formulation having a prolonged time to reach maximum blood concentration compared to immediate-release forms. Research describes a profile that was observed to maintain concentrations over an extended period, which is consistent with the modified-release design. However, follow-up durations were limited, typically lasting only 24 hours for single-dose studies, and sample sizes were modest. This means the research provides insight into short-term changes in absorption, but the evidence that the unique absorption pattern of the retard tablet has not been fully established to associate with different long-term outcomes remains limited.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about C Retard (FAQ)

Q: Why is this medication called 'Retard'?

The term 'Retard' specifically describes the dosage form, classifying it as a modified-release preparation. This means the tablet is engineered to release its active ingredient, Ascorbic Acid, slowly and consistently over an extended period of time within the body. This characteristic is what distinguishes it from standard immediate-release tablets.

Q: Is C Retard the same as Vitamin C?

Yes, C Retard contains the active ingredient Ascorbic Acid, which is the chemical name for Vitamin C. This medicine is a pharmaceutical formulation of that essential nutrient. It is specifically a modified-release tablet designed for sustained delivery of the vitamin.

Q: Is C Retard a controlled substance?

No. According to official regulatory classifications, Ascorbic Acid (Vitamin C) is classified as a water-soluble vitamin and nutritional supplement. It is not listed as a substance scheduled for control under regulatory drug acts.

Q: Can C Retard be bought over the counter?

Preparations containing Ascorbic Acid are generally classified and widely available as an over-the-counter (OTC) nutritional supplement. The specific availability of the C Retard formulation may vary by location and national regulatory guidelines.

Q: Why do doctors prescribe C Retard?

The official intended use for this medicine is to address nutritional needs. It is typically prescribed to prevent or treat an established deficiency of Vitamin C, a condition also known as hypovitaminosis C or scurvy.

Q: How long does it usually take to notice an effect from C Retard?

Research examining the treatment of severe deficiency provides some indication of expected timelines. Initial clinical improvements, such as the reduction of severe fatigue, are described in some studies as beginning within the first one to two weeks of continuous daily use.

Q: Is C Retard generally considered safe to use long-term?

Official information indicates that administration for prolonged periods is generally subject to clinical monitoring. Regulatory documents caution that prolonged administration of high doses is associated with an increased risk of kidney stone formation (oxalate nephropathy) in susceptible individuals. The Tolerable Upper Intake Level for adults is set at 2 grams (2,000 mg) per day.

Q: Can C Retard be used during pregnancy, according to official guidelines?

Regulatory guidelines state that use during pregnancy is generally permitted only to correct a medically diagnosed Vitamin C deficiency. When used, the recommended daily dosage must not be exceeded, as defined in the official product information.

Q: Is it okay to take C Retard with my daily vitamins?

Official interaction documents note that Ascorbic Acid can increase the body's absorption of iron. Taking C Retard with multivitamins containing high amounts of iron may increase the total iron absorbed. Consult with a healthcare professional regarding the co-administration of supplements.

Q: Are there any specific foods to avoid while taking C Retard?

Official regulatory documents defining interactions do not list common foods as needing to be avoided while taking this medicine. Interactions are documented primarily with specific medications, such as aluminum-containing antacids and certain iron preparations.

Q: Can C Retard interfere with blood tests?

Yes, official warnings state that Ascorbic Acid may interfere with certain laboratory tests that rely on oxidation-reduction reactions. This can potentially affect results for tests like blood and urine glucose, nitrite, bilirubin, and white blood cell counts. It is often required that the medicine be stopped prior to specific diagnostic tests.

Q: Is C Retard suitable for use by older adults?

Official documents restrict use for those under 13 years of age and advise caution for older adults due to specific risk factors. This indicates that the standard dosage is typically intended for adolescents and non-elderly adults, but use in the elderly must consider potential risks like oxalate nephropathy (kidney stone formation).

Q: Is it normal to feel a mild stomach upset when starting C Retard?

Yes, mild gastrointestinal complaints are listed in official documents as common adverse reactions. These may include nausea, diarrhea, and mild abdominal pain, and they often occur when first starting the medicine.

Q: What is the typical age range of people who use C Retard?

Official documents define eligibility by stating that the dosage is generally unsuitable for children and adolescents under 13 years of age. Use in older populations requires caution. This suggests that the standard recommended use applies primarily to adolescents and adults.

Q: Does C Retard have a risk of dependence?

No. Regulatory documents classify the active ingredient as a vitamin, and there are no official reports or warnings listed in the safety information regarding drug dependence, abuse potential, or withdrawal syndrome.

Q: Can C Retard make you feel dizzy or lightheaded?

Dizziness is documented in safety monitoring literature as a less common or rare side effect. Although not frequent, it is officially listed as a possible adverse reaction.

Q: What are the official documents saying about discontinuing C Retard?

Official safety warnings state that the medicine must be discontinued if a severe adverse reaction occurs. This includes events such as acute hemolytic anemia in patients with G6PD deficiency or if there is evidence of oxalate nephropathy (kidney disease).

Q: Can C Retard interact with medications for blood pressure?

The official regulatory interaction documents do not specifically list common high blood pressure medications as documented interaction entities. However, Ascorbic Acid can modify the concentration of other drugs sensitive to changes in urine acidity ( pH).

Q: Is C Retard the only drug of its kind available?

The active ingredient, Ascorbic Acid (Vitamin C), is an essential nutrient found in many different supplement and prescription products. The specific 'Retard' (modified-release) formulation, however, is a distinct, specialized dosage form.

Q: Why is C Retard given for certain specific conditions?

The medicine is primarily given to support the body's essential functions. Its active ingredient is a necessary cofactor for key enzymes involved in collagen and tissue synthesis, which is fundamental for wound repair and the maintenance of connective tissues.

Q: Are there any official reports of misuse for C Retard?

Official regulatory documents do not list drug abuse or misuse potential for Ascorbic Acid. Adverse event reporting systems primarily track reported side effects and issues related to product quality and safety.

Q: How common is an allergic reaction to C Retard?

A known allergy (hypersensitivity) to the active substance or excipients is a contraindication, meaning the drug must not be used by affected individuals. Rarer skin reactions, such as rash or hives, are documented in the less common or rare adverse reaction categories.

How should C Retard be stored and disposed of?

Storage and Disposal of C Retard

Official regulatory labeling dictates the specific conditions necessary for storing C Retard (ascorbic acid, modified-release preparation) to maintain its quality and protect the public.

Required Storage Conditions

Temperature: Store at a Controlled Room Temperature, which ranges from 20^circC to 25^circC (68^circF to 77^circF). Storage must not exceed 30^circC.
Protection: The medicine must be protected from light and kept dry to maintain product stability.
Packaging: Store the product in the original container, which should be kept tightly closed.

Disposal and Child Safety

Child Safety: C Retard is required to be kept out of the reach and sight of children.
Disposal: Unused or expired medication must be disposed of according to local requirements. The product must not be disposed of via wastewater or household waste.

C Retard